Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia-Reference-Cited by-同舟云学术

Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia

Published:2021-01-01 Issue:1 Volume:7 Page:42
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Atallah Ehab¹,Schiffer Charles A.²,Radich Jerald P.³,Weinfurt Kevin P.⁴,Zhang Mei-Jie⁵,Pinilla-Ibarz Javier⁶,Kota Vamsi⁷,Larson Richard A.⁸,Moore Joseph O.⁹,Mauro Michael J.¹⁰,Deininger Michael W. N.¹¹,Thompson James E.¹²,Oehler Vivian G.³,Wadleigh Martha¹³,Shah Neil P.¹⁴,Ritchie Ellen K.¹⁵,Silver Richard T.¹⁵,Cortes Jorge⁷,Lin Li⁴,Visotcky Alexis⁵,Baim Arielle¹,Harrell Jill³,Helton Bret³,Horowitz Mary¹,Flynn Kathryn E.¹

Affiliation:

1. Department of Medicine, Medical College of Wisconsin, Milwaukee

2. Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan

3. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington

4. Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina

5. Division of Biostatistics, Medical College of Wisconsin, Milwaukee

6. Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

7. Georgia Cancer Center, Augusta University Medical Center, Augusta

8. Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, Illinois

9. Duke Cancer Institute, Durham, North Carolina

10. Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

11. Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City

12. Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York

13. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

14. Department of Medicine, University of California at San Francisco, San Francisco

15. Division of Medicine, Department of Medical Oncology and Hematology, Weill Medical College of Cornell University, New York, New York

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2772842/jamaoncology_atallah_2020_oi_200084_1609897940.7478.pdf

Reference38 articles.

1. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population.;Bower;J Clin Oncol,2016

2. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.;Druker;N Engl J Med,2006

3. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.;Hahn;J Clin Oncol,2003

4. Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review.;Efficace;Leuk Res,2013

5. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.;Mahon;Lancet Oncol,2010

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment‐free remission as a new goal in the management of chronic myeloid leukemia: Clinical and biological aspects;Hematological Oncology;2024-09

2. Quality of life and psychosocial impact on patients with blood disorders: An empirical study from patients’ perspectives in Saudi Arabia;Nutrition and Health;2024-08-31

3. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08

4. Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients;European Journal of Haematology;2024-07-12